Literature DB >> 23055188

Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer.

Yu-Jing Fang1, Guo-Qiang Wang, Zhen-Hai Lu, Lin Zhang, Ji-Bin Li, Xiao-Jun Wu, Pei-Rong Ding, Qing-Jian Ou, Mei-Fang Zhang, Wu Jiang, Zhi-Zhong Pan, De-Sen Wan.   

Abstract

Estrogen receptor beta (ERβ) and TROP2 expressed in colon carcinoma and might play an important role there. We explored the relationship of ERβ and TROP2 expression with the prognosis of early-stage colon cancer. ERβ and TROP2 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 220 Chinese patients with T(3)N(0)M(0) (stage IIa) and T(4)N(0)M(0) (stage IIb) colon cancer in the Cancer Center, Sun Yat-sen University, who underwent curative surgical resection between 1995 and 2003. The Cox proportional hazards regression model was applied to analyze the overall survival (OS) data, and the ROC curve, Kaplan-Meier estimate, log rank test, and Jackknife method were used to show the effect of ERβ and TROP2 expression at different stages of cancer. The 5-year survival rates were not significantly different between the patients with stage IIa and stage IIb colon cancer (83 vs. 80 %, respectively). The high expression of ERβ was related to decreasing OS in stage IIa and stage IIb colon cancer, while the high expression of TROP2 was related to decreasing OS in stage IIb colon cancer. The expression of ERβ and TROP2 has tumor-suppressive and tumor-promoting effect in stage IIa and stage IIb colon cancer, respectively.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055188     DOI: 10.1007/s13277-012-0484-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Estrogen receptor beta is expressed in human colorectal adenocarcinoma.

Authors:  D Witte; M Chirala; A Younes; Y Li; M Younes
Journal:  Hum Pathol       Date:  2001-09       Impact factor: 3.466

2.  Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice.

Authors:  Nancy L Cho; Sara H Javid; Adelaide M Carothers; Mark Redston; Monica M Bertagnolli
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

3.  Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma.

Authors:  Liang Liu; Minni Chirala; Mamoun Younes
Journal:  Anticancer Res       Date:  2004 Sep-Oct       Impact factor: 2.480

4.  Estrogen receptor beta expression in vascular neoplasia: an analysis of 53 benign and malignant cases.

Authors:  Andrea T Deyrup; Maria Tretiakova; Andrey Khramtsov; Anthony G Montag
Journal:  Mod Pathol       Date:  2004-11       Impact factor: 7.842

5.  Estrogen receptor-beta expression in human testicular germ cell tumors.

Authors:  Vernon Pais; Irwin Leav; Kin-Mang Lau; Zhong Jiang; Shuk-Mei Ho
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

6.  Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation.

Authors:  P A Konstantinopoulos; A Kominea; G Vandoros; G P Sykiotis; P Andricopoulos; I Varakis; G Sotiropoulou-Bonikou; A G Papavassiliou
Journal:  Eur J Cancer       Date:  2003-06       Impact factor: 9.162

7.  Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.

Authors:  Alessandro D Santin; Fenghuang Zhan; Stefania Bellone; Michela Palmieri; Stefania Cane; Eliana Bignotti; Simone Anfossi; Murat Gokden; Donna Dunn; Juan J Roman; Timothy J O'Brien; Erming Tian; Martin J Cannon; John Shaughnessy; Sergio Pecorelli
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

8.  Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.

Authors:  Keiko Abe; Yasuhiro Miki; Katsuhiko Ono; Miki Mori; Hideaki Kakinuma; Yuki Kou; Nobutaka Kudo; Masashi Koguchi; Hiromichi Niikawa; Satoshi Suzuki; Dean B Evans; Shunichi Sugawara; Takashi Suzuki; Hironobu Sasano
Journal:  Hum Pathol       Date:  2009-10-01       Impact factor: 3.466

9.  Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.

Authors:  Rafael Cubas; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Mol Cancer       Date:  2010-09-21       Impact factor: 27.401

10.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer.

Authors:  D Fong; P Moser; C Krammel; J M Gostner; R Margreiter; M Mitterer; G Gastl; G Spizzo
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more
  3 in total

1.  Chemotherapy agents-induced immunoresistance in lung cancer cells could be reversed by trop-2 inhibition in vitro and in vivo by interaction with MAPK signaling pathway.

Authors:  Xi Wang; Min Long; Ke Dong; Fang Lin; Yuanyuan Weng; Yongri Ouyang; Li Liu; Junxia Wei; Xi Chen; Ting He; Hui-Zhong Zhang
Journal:  Cancer Biol Ther       Date:  2013-09-04       Impact factor: 4.742

2.  Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.

Authors:  George Pentheroudakis; Georgia Raptou; Vassiliki Kotoula; Ralph M Wirtz; Eleni Vrettou; Vasilios Karavasilis; Georgia Gourgioti; Chryssa Gakou; Konstantinos N Syrigos; Evangelos Bournakis; Grigorios Rallis; Ioannis Varthalitis; Eleni Galani; Georgios Lazaridis; George Papaxoinis; Dimitrios Pectasides; Gerasimos Aravantinos; Thomas Makatsoris; Konstantine T Kalogeras; George Fountzilas
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

3.  TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors.

Authors:  Shailendra Kapoor
Journal:  Tumour Biol       Date:  2012-11-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.